Clinical significance of expressions of bcl-2 and BCRP in diffuse large B cell lymphoma
10.3760/cma.j.issn.1009-9921.2011.06.011
- VernacularTitle:bcl-2与乳腺癌耐药蛋白基因在弥漫大B细胞淋巴瘤中表达的意义
- Author:
Hexin LI
;
Liping SU
;
Xiaolian WEN
- Publication Type:Journal Article
- Keywords:
Lymphoma,non-Hodgkin;
Multidrug resistance-associated proteins;
bcl-2;
BCRP;
Prognosis
- From:
Journal of Leukemia & Lymphoma
2011;20(6):373-375
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the expression of b-cell lymphoma/leukemia-2 (bcl-2) and breast cancer drug-resistant protein (BCRP) in diffuse large B cell lymphoma (DLBCL) and their correlation. Methods Using flow cytometry (FCM) and semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) assay the expressions of BCRP gene was analysed in 40 DLBCL samples. bcl-2 protein were measured by immunohistochemistry on paraffin-embedded slices in 40 cases of DLBCL. Results The positive expression rate of bcl-2 and BCRP protein were 60.0 % (24/40) and 37.5 % (15/40) in 40 patients with DLBCL respectively. There was significant differences between positive group and negative groups (x2 = 5.7618,P <0.05; x2 = 6.5541,P <0.05). There was no significant correlation between Bcl-2 and BCRP gene in effective treatment group and therapies group or progress group (x2 = 2.0263,P >0.05). Conclusion BCRP may play an important role in DLBCL primary much medicine drug-resistant,thus it may be a useful prediction of chemotherapeutic treatment and risk of relapse. The level bcl-2 expression was closely related with the grade of malignancy and the prognosis of DLBCL. There was no significant correlation between bcl-2 and BCRP gene. The detection of bcl-2 and BCRP gene played an important role in evaluating DLBCL outcome.
